Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C. Tward JD, et al. Among authors: agarwal n. Clin Genitourin Cancer. 2020 Aug;18(4):274-283.e5. doi: 10.1016/j.clgc.2019.11.023. Epub 2020 Mar 19. Clin Genitourin Cancer. 2020. PMID: 32335059
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.
Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G. Maughan BL, et al. Among authors: agarwal n. Clin Genitourin Cancer. 2013 Sep;11(3):316-20. doi: 10.1016/j.clgc.2012.12.007. Epub 2013 Jan 16. Clin Genitourin Cancer. 2013. PMID: 23332638 Clinical Trial.
Management of hormone-sensitive metastatic prostate cancer.
Agarwal N, Hussain M. Agarwal N, et al. Hematol Oncol Clin North Am. 2013 Dec;27(6):1221-41, viii. doi: 10.1016/j.hoc.2013.08.007. Epub 2013 Sep 21. Hematol Oncol Clin North Am. 2013. PMID: 24188260 Review.
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Agarwal N, et al. Clin Genitourin Cancer. 2014 Apr;12(2):130-7. doi: 10.1016/j.clgc.2013.09.002. Epub 2013 Sep 28. Clin Genitourin Cancer. 2014. PMID: 24220220 Free PMC article.
2,502 results